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needed to assess the influence of each type of symptom
on different components of psychological well-being, ad-
ditional QoL domains which may be affected, and psy-
chosocial correlates which may mediate between symp-
toms and outcome in menopausal women.
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Hormone replacement therapy (HRT) can be useful for
preventing osteoporosis and improving serum cholesterol
levels among postmenopausal women. However, post-
menopausal HRT is associated with minor adverse events,
such as abnormal vaginal bleeding and breast pain or dis-
comfort, and may be associated with increased risks of
breast and uterine cancer. 
OBJECTIVE: To compare resource utilization for uterine
and breast disease screening, diagnostic evaluation, and
treatment among postmenopausal HRT users to non-
HRT users, over a 2-year period. 
METHODS: The study uses 1993–1996 MarketScan®
data. Women at least 50 years old were identified as new
HRT users based on both an estrogen and a progestin claim
within 45 days of each other, with no evidence of either
therapy during the prior 6 months. The sample of HRT
users included 970 women. A random sample of 2236
women with no HRT use over the study period was se-
lected as a control group. 
RESULTS: HRT users were more likely than non-users to
have visits with each of the following diagnoses: postmeno-
pausal bleeding, metrorrhagia, dysfunctional or functional
uterine hemorrhage, or abnormal bleeding from the female
genital tract. HRT users were more likely to have uterine-
related procedures such as ultrasound or hysteroscopy,
and more likely to have some breast-related procedures,
such as mammography, ultrasound of the breast, biopsy of
breast, or drainage of cysts. 
CONCLUSIONS: Postmenopausal HRT recipients were
more likely to experience abnormal uterine bleeding and
to have procedures related to uterine bleeding. Future
evaluations of the cost-effectiveness of HRT as a long-
term prevention strategy should incorporate the costs of
resource utilization related to adverse events of HRT in
addition to its clinical benefits.
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OBJECTIVE: To determine the cost-effectiveness of short-
term (5 years) versus long-term (10 years) ERT in post-
menopausal women, in reducing the incidence of hip frac-
tures. 
METHODS: Data were derived from previously pub-
lished articles on the effect of ERT in the reduction of hip
fractures and long-term complications such as breast can-
cer and endometrial cancer in postmenopausal women.
Rate of reduction in hip fractures was used as a measure
of prevention of osteoporosis. From previous articles, we
obtained probabilities and costs of procedures associated
with hip fracture, drug therapy, and long-term complica-
tions. The cost of therapy included only the direct costs
(including costs to treat complications resulting from
ERT such as breast cancer and endometrial cancer) since
this study was performed from a third-party payer’s per-
spective. The effectiveness measure was calculated as the
life-years gained from reduction in hip fractures. 
RESULTS: The net cost of 5-year ERT was $7433 and
for the 10-year therapy the net cost was $5445. The life-
years saved increased from .06 life-years saved (LY) with
5-year therapy to 0.14 LY with 10-year therapy. Without
further analysis, it was seen that the 10-year therapy
costs less and patients survive longer. 
CONCLUSION: Our study showed that long-term estro-
gen replacement therapy (10 years) was more cost-effective
than short-term therapy (5 years) in the treatment of os-
teoporosis in postmenopausal women and hence women
who were on ERT should be placed on it for 10 years.
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OBJECTIVE: To determine if Viagra was more cost-ef-
fective than Muse in the treatment of male erectile dys-
function. 
METHODS: Data on the efficacy of the two drugs was
obtained from previous studies on these drugs. Our study
period was set at 6 months. The study patients were
males aged between 18–75 years, in a stable relationship
with a female partner for at least 6 months, and diag-
nosed with erectile dysfunction for 6 months or longer.
The patients received either Viagra or Muse for treatment
of their erectile dysfunction. The study was performed
from a payer’s perspective and hence only included cost
of the drug and related hospitalizations. Data were also
derived from clinicians about the probability of compli-
cations, and from some hospitals to obtain the costs of
hospitalizations and emergency room visits. The effec-
tiveness measure in our study was the percentage of suc-
cessful intercourse at the end of the 6-month period. 
